MRK
Merck·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
FDA Approved
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MRK
Merck & Co., Inc.
One of the largest pharmaceutical company in the globe that develops prescription drugs in the areas of diabetes, obesity, respiratory, cardiovascular, and women's health
126 East Lincoln Avenue, Rahway, New Jersey 07065
Human health medicines and vaccine products
Merck & Co., Inc. was incorporated in New Jersey in 1970. The company is a global healthcare company that provides innovative health solutions through its prescription drugs, including biological therapies, vaccines and animal health products. The company's operations are mainly managed on a product basis and include two operating divisions: Pharmaceuticals and Animal Health International.
Earnings Call
Q1/2025
Estimate EPS2.14
Actual EPS2.22
Estimate Revenue15.33B
Actual Revenue15.53B
Mineralys Therapeutics' Q1 2025: Key Contradictions in Pipeline Progress, Financial Guidance, and Merck Collaboration
May 20,2025 07:18
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS2.03
Actual EPS2.13
Estimate Revenue15.87B
Actual Revenue15.81B
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics
Aug 10,2025 04:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
MRK has released its 2025 Q3 earnings. EPS was reported at 2.58, versus the expected 2.35, beating expectations. The chart below visualizes how MRK has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MRK has released its 2025 Q3 earnings report, with revenue of 17.28B, reflecting a YoY change of 3.72%, and net profit of 5.79B, showing a YoY change of 83.07%. The Sankey diagram below clearly presents MRK's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
